Cougar Biotechnology to Present at Lazard Capital Markets 5th Annual Healthcare Conference
November 11 2008 - 4:05PM
Business Wire
Cougar Biotechnology, Inc. (NASDAQ:CGRB) today announced that Alan
H. Auerbach, Chief Executive Officer and President of Cougar, will
present at the Lazard Capital Markets 5th Annual Healthcare
Conference on Tuesday, November 18 at 1:40 p.m. EST at The St.
Regis Hotel in New York City. Mr. Auerbach will provide a company
overview and update on the status of Cougar�s current clinical
development programs. Interested investors may access a live audio
webcast by visiting the Investor Relations section of the Company�s
Web site at www.cougarbiotechnology.com. The presentation will be
archived on the Web site and available for 30 days. About Cougar
Biotechnology Cougar Biotechnology, Inc. is a Los Angeles-based
biotechnology company established to in-license and develop
clinical stage drugs, with a specific focus on the field of
oncology. Cougar�s oncology portfolio includes CB7630, a targeted
inhibitor of the 17alpha-hydroxylase/c17,20 lyase enzyme, which is
currently being tested in a Phase III clinical trial in prostate
cancer; CB3304, an inhibitor of microtubule dynamics, which is
currently in a Phase I trial in multiple myeloma; and CB1089, an
analog of vitamin D, which has been clinically tested in a number
of solid tumor types. Further information about Cougar
Biotechnology can be found at www.cougarbiotechnology.com.
Cougar Biotechnology (MM) (NASDAQ:CGRB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cougar Biotechnology (MM) (NASDAQ:CGRB)
Historical Stock Chart
From Jul 2023 to Jul 2024